Electromed: Strong Margins, Strong Growth, Large Runway

Impact · against what's priced in

Electromed's record Q3 net income and expanding operating margins suggest a strong trajectory in an underpenetrated market. Regulatory tailwinds from CMS and complementary drug approvals provide structural growth catalysts that likely outweigh current valuation.

ELMD+0.80

No priced-in read yet

In context

Record net income of $3.0 million and an operating margin increase to 20.4% demonstrate strong execution, while a new CMS rule and approved bronchiectasis drugs expand the addressable market.

Read from the article alone

• earnings▲<1%
• healthcare
• ELMD
• bronchiectasis
• cms rules
• margin expansion
• medical devices

Top 1 mover · tap to explore